Crohn’s approval, new VC round, direct offerings, and potential asset sales

Gene therapy, minor legislation, a $625M series D, and four companies raise $373M

Pharma buys, pharma splits, pharma trades, and oncology biobucks from pharma

Pox-machina, an oncology acquisition, and we look at $360M worth of biotech funding

An $11.6B yes, $11.7B delay, drop the AIC with GLP, and a billion bio-bucks

Resets for biotech, antibiotics approval not enough, continued consolidation, and a normal deal

Pharma Q1 reports are rolling in, COVID boost turned sustainable, and weight loss battle looms

Drops for reading, a $220M raise, and an acquisition straight out of the movies

The FDA asks for more diversity, $1B for injectors, $2B for a one-trick pony, and $68M to make DNA

Viral therapies, rare disease approvals, and lab space premiums

Big compensation, mild mergers, a Kite in an updraft, and tightening the biotech belt

$2 billion in capital raises mostly by companies that start with the letter A.

Case closed on patents, Alzheimer’s data, generic approvals, and expanded approvals.

Technology for inclusion, layoffs, oncology approvals, and $200M for a tech platform.

Who owns CRISPR, a collaboration, the classics, and more money for biotech

CRISPR works, the opioid epidemic makes amends (sort of), and the SPAC that wasn’t

The PD1 that lost, biopharma earns FDA approval, and the Biotech market is cool not dead

Dragons over unicorns, to CRISPR and beyond, spin-out-and-sell, and expanded approvals

Bispecific antibodies, ocular oncology, Biogen sells, Lilly Builds, and the treatment of a lifetime

Psychedelic SPACs, eczema frenzy, bio-outs without the biobucks, back on track, and the mega-deal that wasn’t